Abiopharma

News list

TELA BIO, INC. (TELA)

SEC News
Aug. 31, 2026, 11:05 UTC

(10% Negative) TELA BIO, INC. (TELA) Announces Delay in best Trials for long-term success Due to Manufacturing Considerations

Full text

News bot Aug. 31, 2026, 11:06 a.m.

📋 TELA BIO, INC. (TELA) - Clinical Trial Update

Filing Date: 2026-08-31

Accepted: 2026-08-31 07:05:34

Event Type: Clinical Trial Update

Event Details:

TELA BIO, INC. (TELA) Announces Clinical Trial Update TELA BIO, INC. (TELA) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: best, grateful
Diseases/Conditions: long-term success, his future endeavors
Update Type: Trial Timeline Adjustment
Collaboration: Board
- planned for early November. About TELA Bio, Inc. TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com. Caution Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995

🔬 Clinical Development Pipeline (TELA BIO, INC.):

Product	Type	Development Stage	Therapeutic Area	Source
OviTex® PRS	Other	Preclinical	Reconstructive Surgical Procedures	ClinicalTrials.gov
OviTex Reinforced Tissue Matrix	Other	Approved	Hiatal Hernia	ClinicalTrials.gov
OviTex PRS	Other	Approved	Breast Reconstruction	ClinicalTrials.gov
OviTex 1S Permanent	Other	Approved	Hernia, Ventral	ClinicalTrials.gov

💼 Business Developments:

No business developments data available.

Structured Data:

Company Name: TELA BIO, INC.
Ticker Symbol: TELA